Почетна › Рак на дојка › Ново Мексико
Клинички испитувања за Рак на дојка во Ново Мексико
19 студии за Рак на дојка бараат учесници на локации во Ново Мексико.
Градови во Ново Мексико
Официјален текст на студијата (англиски)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Presbyterian Medical Group, Albuquerque
Се регрутираФаза 3
Возраст од 18 до 100 · Сите полови · Ажурирано 2.10.2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Lovelace Medical Center-Saint Joseph Square, Albuquerque
- University of New Mexico Cancer Center, Albuquerque
- Lovelace Women's Hospital, Albuquerque
- и уште 3
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
Возраст од 40 до 75 · Сите полови · Ажурирано 2.10.2026 · NCT05334069A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- The University of New Mexico, Albuquerque
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT07102381A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Presbyterian Kaseman Hospital ( Site 0072), Albuquerque
- University of New Mexico Comprehensive Cancer Center ( Site 0047), Albuquerque
- Presbyterian Rust Jorgensen Cancer ( Site 0073), Rio Rancho
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07060807The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Lovelace Medical Center - Saint Joseph Square, Albuquerque
- Lovelace Women's Hospital, Albuquerque
- Presbyterian Kaseman Hospital, Albuquerque
- и уште 3
Се регрутираФаза 3
Возраст 60 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06377852A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Albuquerque
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06103864Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Santa Fe
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- New Mexico Oncology & Hematology Consultants, Albuquerque
Се регрутира
Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT07214532A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Exigent Research LLC/New Mexico Oncology Hematology Consultants Ltd., Albuquerque
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 15.9.2026 · NCT06492616A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Albuquerque
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 11.9.2026 · NCT05123482A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- San Juan Oncology Associates, Farmington
Се регрутираФаза 1
Возраст од 18 до 55 · Жени · Ажурирано 9.9.2026 · NCT07310420Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- University of New Mexico Cancer Center, Albuquerque
- Presbyterian Kaseman Hospital, Albuquerque
- Memorial Medical Center-Las Cruces, Las Cruces
- и уште 1
Се регрутираФаза 3
Возраст од 18 до 60 · Жени · Ажурирано 2.9.2026 · NCT05879926Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Presbyterian Kaseman Hospital, Albuquerque
- Presbyterian Rust Cancer Center, Rio Rancho
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.6.2026 · NCT05696626De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- University of New Mexico Cancer Center, Albuquerque
Се регрутираФаза 3
Возраст од 50 до 70 · Сите полови · Ажурирано 23.4.2026 · NCT04852887SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
- University of New Mexico, Albuquerque
Се регрутира
Возраст 18 и постари · Сите полови · Ажурирано 7.4.2026 · NCT06896474Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Lovelace Medical Center-Saint Joseph Square, Albuquerque
- University of New Mexico Cancer Center, Albuquerque
- Lovelace Women's Hospital, Albuquerque
- и уште 3
Се регрутираНабљудувачка студија
Возраст 18 и постари · Сите полови · Ажурирано 17.3.2026 · NCT06418204SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Albuquerque
Се регрутираНабљудувачка студија
Сите возрасти · Сите полови · Ажурирано 28.10.2025 · NCT03452774S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- University of New Mexico Cancer Center, Albuquerque
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 8.10.2025 · NCT03418961BostonGene and Exigent Genomic INsight Study
- New Mexico Cancer Center, Albuquerque
Се регрутираНабљудувачка студија
Возраст 18 и постари · Сите полови · Ажурирано 17.2.2025 · NCT06272864Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.